Can low zinc contribute to low free T3 and thyroid antibody activity?

Zinc is a critical micronutrient required for both the metabolic activation of thyroid hormones and the maintenance of peripheral immunological self-tolerance.

Thyroid metabolism and receptor function

• Enzymatic conversion: Zinc acts as an essential cofactor for type I (D1) and type II (D2) iodothyronine deiodinases, which catalyze the outer-ring deiodination of thyroxine (T4) into the biologically active triiodothyronine (T3). Zinc deficiency can reduce hepatic D1 activity by up to 67%, leading to compromised peripheral conversion and lower circulating free T3.
• Receptor transcription: At the cellular level, thyroid hormone receptors (TRα and TRβ) rely on C4-type zinc-finger DNA-binding domains. Losing zinc coordination structurally deforms these domains, abolishing the receptor's ability to bind to thyroid hormone response elements (TREs) and execute transcription. Supplementing with 30 mg/day of zinc has been shown to successfully raise free T3 levels and improve the FT3:FT4 ratio.

Immune tolerance and autoimmunity

• T-cell polarization: Physiological zinc levels preserve immune tolerance by stabilizing CD4+Foxp3+ regulatory T cells (Tregs). Conversely, zinc deficiency compromises Treg suppressive capacity—partially by reducing miR-146a expression and altering Foxp3 stability—while promoting pro-inflammatory Th17 cell polarization via the IL-6-STAT3 signaling pathway.
• Thyroid autoantibodies: This Th17-dominant inflammatory skewing disrupts self-tolerance, facilitating the production of thyroid peroxidase (TPOAb) and thyroglobulin (TgAb) autoantibodies. Clinically, low serum zinc levels (<70 µg/dL) are associated with elevated autoantibody titers and an estimated 10-fold increased risk of thyroid autoimmunity, though correcting the deficiency does not reliably reverse established autoantibody titers.

Bottom line

• Zinc deficiency directly contributes to low free T3 and elevated thyroid autoantibodies by impairing deiodinase activity and cellular receptor binding, while simultaneously disrupting regulatory T-cell stability to drive autoimmune thyroid responses.